TORNTPHARM Q1 FY27 results at a glance
TORRENT PHARMACEUTICALS L Q1 FY27 key results metrics| Quarter | Q1 FY27 |
|---|
| Quarter ended | 30 Jun 2026 |
|---|
| Revenue | ₹4,835 cr |
|---|
| Revenue YoY | +54.6% |
|---|
| Operating profit | ₹1,071 cr |
|---|
| Operating margin | 22.2% |
|---|
| Net profit | ₹566 cr |
|---|
| Net profit YoY | +3.3% |
|---|
| Net profit QoQ | +45.5% |
|---|
| Net margin | 11.7% |
|---|
| Basic EPS | ₹14.87 |
|---|
| TTM revenue | ₹15,460 cr |
|---|
| TTM net profit | ₹2,181 cr |
|---|
| TTM net margin | 14.1% |
|---|
TORNTPHARM Q1 FY27 results: what the numbers say
TORRENT PHARMACEUTICALS L (TORNTPHARM) has reported its Q1 FY27 results for the quarter ended 2026-06-30. The company posted revenue of ₹4,835 cr and a net profit of ₹566 cr, translating into earnings per share of ₹14.87.
Compared with the same quarter a year earlier, revenue grew sharply by +54.6% and net profit grew by +3.3%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹1,071 cr, an operating margin of 22.2% versus 26.6% a year ago — a contraction of 4.4 percentage points.
TORNTPHARM quarter-wise results table
Revenue
₹4,835 cr
+54.6% YoY
Net profit
₹566 cr
+3.3% YoY
Operating profit
₹1,071 cr
+28.9% YoY
TORRENT PHARMACEUTICALS L (TORNTPHARM) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q1 FY272026-06-30 | ₹4,835 cr | ₹1,071 cr | ₹566 cr | 22.2% | 11.7% | ₹14.87 | +3.3% | +45.5% |
| Q4 FY262026-03-31 | ₹4,128 cr | ₹848 cr | ₹389 cr | 20.5% | 9.4% | ₹11.51 | — | -38.7% |
| Q3 FY262025-12-31 | ₹3,251 cr | ₹882 cr | ₹635 cr | 27.1% | 19.5% | ₹18.77 | — | +7.4% |
| Q2 FY262025-09-30 | ₹3,246 cr | ₹879 cr | ₹591 cr | 27.1% | 18.2% | ₹17.45 | — | +7.8% |
| Q1 FY262025-06-30 | ₹3,128 cr | ₹831 cr | ₹548 cr | 26.6% | 17.5% | ₹16.19 | — | — |
| TTM (last 4 quarters) | ₹15,460 cr | ₹3,680 cr | ₹2,181 cr | 23.8% | 14.1% | ₹62.60 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
TORNTPHARM quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
TORRENT PHARMACEUTICALS L quarterly income statement| Particulars | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q2 FY262025-09-30 | Q1 FY262025-06-30 |
|---|
| Revenue / Sales | ₹4,835 cr | ₹4,128 cr | ₹3,251 cr | ₹3,246 cr | ₹3,128 cr |
|---|
| Total expenses | ₹3,764 cr | ₹3,280 cr | ₹2,369 cr | ₹2,367 cr | ₹2,297 cr |
|---|
| Gross profit | ₹3,672 cr | ₹3,113 cr | ₹2,452 cr | ₹2,446 cr | ₹2,354 cr |
|---|
| Operating profit (EBIT) | ₹1,071 cr | ₹848 cr | ₹882 cr | ₹879 cr | ₹831 cr |
|---|
| Operating margin | 22.2% | 20.5% | 27.1% | 27.1% | 26.6% |
|---|
| Interest cost | ₹305 cr | ₹236 cr | ₹45 cr | ₹48 cr | ₹56 cr |
|---|
| Profit before tax | ₹733 cr | ₹529 cr | ₹814 cr | ₹791 cr | ₹738 cr |
|---|
| Tax expense | ₹167 cr | ₹165 cr | ₹179 cr | ₹200 cr | ₹190 cr |
|---|
| Effective tax rate | 22.8% | 31.2% | 22.0% | 25.3% | 25.7% |
|---|
| Net profit (PAT) | ₹566 cr | ₹389 cr | ₹635 cr | ₹591 cr | ₹548 cr |
|---|
| Net profit margin | 11.7% | 9.4% | 19.5% | 18.2% | 17.5% |
|---|
| Basic EPS | ₹14.87 | ₹11.51 | ₹18.77 | ₹17.45 | ₹16.19 |
|---|
| Diluted EPS | ₹14.87 | ₹11.51 | ₹18.77 | ₹17.45 | ₹16.19 |
|---|
TORNTPHARM results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|
| Revenue YoY | +54.6% | — | — | — | — |
|---|
| Revenue QoQ | +17.1% | +27.0% | +0.2% | +3.8% | — |
|---|
| Operating profit YoY | +28.9% | — | — | — | — |
|---|
| Operating profit QoQ | +26.3% | -3.9% | +0.3% | +5.8% | — |
|---|
| Net profit YoY | +3.3% | — | — | — | — |
|---|
| Net profit QoQ | +45.5% | -38.7% | +7.4% | +7.8% | — |
|---|
| EPS YoY | -8.2% | — | — | — | — |
|---|
| EPS QoQ | +29.2% | -38.7% | +7.6% | +7.8% | — |
|---|
TORNTPHARM annual results history
Full-year performance for TORRENT PHARMACEUTICALS L, useful for reading each quarter in context.
TORRENT PHARMACEUTICALS L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|
| Revenue / Sales | ₹13,753 cr | ₹11,317 cr | ₹10,562 cr | ₹9,464 cr |
|---|
| Total expenses | ₹10,313 cr | ₹8,391 cr | ₹7,990 cr | ₹7,324 cr |
|---|
| Gross profit | ₹10,228 cr | ₹8,433 cr | ₹7,775 cr | ₹6,636 cr |
|---|
| Operating profit (EBIT) | ₹3,440 cr | ₹2,926 cr | ₹2,572 cr | ₹2,140 cr |
|---|
| Operating margin | 25.0% | 25.9% | 24.4% | 22.6% |
|---|
| Interest cost | ₹385 cr | ₹251 cr | ₹353 cr | ₹332 cr |
|---|
| Profit before tax | ₹2,872 cr | ₹2,673 cr | ₹2,352 cr | ₹1,847 cr |
|---|
| Tax expense | ₹734 cr | ₹762 cr | ₹696 cr | ₹602 cr |
|---|
| Effective tax rate | 25.6% | 28.5% | 29.6% | 32.6% |
|---|
| Net profit (PAT) | ₹2,163 cr | ₹1,911 cr | ₹1,656 cr | ₹1,245 cr |
|---|
| Net profit margin | 15.7% | 16.9% | 15.7% | 13.2% |
|---|
| Basic EPS | ₹63.92 | ₹56.47 | ₹48.94 | ₹36.79 |
|---|
| Diluted EPS | ₹63.92 | ₹56.47 | ₹48.94 | ₹36.79 |
|---|
Revenue trend and demand read-through
Topline for Q1 FY27 came in at ₹4,835 cr against ₹3,128 cr in Q1 FY26, and ₹4,128 cr in the preceding Q4 FY26 quarter.
On a sequential basis revenue grew +17.1%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹3,764 cr, or 77.8% of revenue, with operating profit grew +28.9% year on year.
Margins, tax and profitability
Net profit of ₹566 cr works out to a net margin of 11.7% compared with 17.5% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, TORRENT PHARMACEUTICALS L reported profit before tax of ₹733 cr, a tax charge of ₹167 cr (effective rate 22.8%), interest cost of ₹305 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹389 cr in Q4 FY26 to ₹566 cr in Q1 FY27, a change of +45.5%.
Trailing twelve months and annual context
Across the trailing four quarters TORRENT PHARMACEUTICALS L has generated revenue of ₹15,460 cr and net profit of ₹2,181 cr, a trailing net margin of 14.1%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹13,753 cr with net profit of ₹2,163 cr and EPS of ₹63.92, versus the prior year where revenue grew +21.5% and profit grew +13.2%.
What to watch in the next TORNTPHARM quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
TORRENT PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
TORNTPHARM results coverage
No results report published for TORNTPHARM yet — our desk covers each quarter within minutes of the filing.
TORNTPHARM quarterly results FAQs
What were TORRENT PHARMACEUTICALS L (TORNTPHARM) Q1 FY27 results?
In Q1 FY27 (quarter ended 30 Jun 2026), TORRENT PHARMACEUTICALS L reported revenue of ₹4,835 cr and net profit of ₹566 cr, a change of +3.3% year on year on +54.6% revenue growth. EPS stood at ₹14.87.
What is TORNTPHARM profit margin in Q1 FY27?
TORRENT PHARMACEUTICALS L posted a net profit margin of 11.7% and an operating margin of 22.2% in Q1 FY27. On a trailing twelve-month basis, revenue is ₹15,460 cr and net profit ₹2,181 cr.
Did TORNTPHARM results beat the previous quarter?
TORRENT PHARMACEUTICALS L net profit changed +45.5% quarter on quarter, from ₹389 cr in Q4 FY26 to ₹566 cr in Q1 FY27.
When are TORRENT PHARMACEUTICALS L (TORNTPHARM) quarterly results?
TORRENT PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see TORNTPHARM latest quarterly results?
Results coverage for TORNTPHARM will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the TORNTPHARM stock page.
What is TORRENT PHARMACEUTICALS L annual revenue and profit?
For FY26, TORRENT PHARMACEUTICALS L reported full-year revenue of ₹13,753 cr and net profit of ₹2,163 cr, with EPS of ₹63.92.
How many quarterly results has TORNTPHARM declared recently?
Past results dates for TORNTPHARM will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
